Diabetes Care Drugs Market Report 2025

The diabetes care drugs market size has grown strongly in recent years. It will grow from $69.55 billion in 2024 to $73.48 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to several factors, including the rising global prevalence of diabetes, an increasing aging population, sedentary lifestyles, poor dietary habits, rising obesity rates, and the growing adoption of personalized medicine in diabetes care.

The diabetes care drugs market size is expected to see strong growth in the next few years. It will grow to $90.5 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth projected for the forecast period can be attributed to several factors, including the emergence of biosimilar insulins, the development of combination therapies and fixed-dose formulations, a growing focus on continuous glucose monitoring and closed-loop systems, and increasing awareness and prevention programs aimed at prediabetes. Key trends to watch during this period include the integration of continuous glucose monitoring with smart drug delivery systems, the adoption of digital patient engagement platforms, the rise of wearable drug delivery devices, advancements in peptide or polymer-based sustained-release formulations, and the integration of pharmacogenomics for personalized dosing.

The increasing number of diabetic patients is expected to drive the growth of the diabetes care drugs market. Diabetic patients are individuals diagnosed with diabetes mellitus, a chronic condition that affects the body’s ability to process blood sugar (glucose). The rise in diabetes cases is mainly attributed to unhealthy diets and sedentary lifestyles, which contribute to obesity and insulin resistance. Diabetes care drugs are essential for managing blood glucose levels in both type 1 and type 2 diabetes, helping to prevent complications, stabilize sugar levels, improve overall health, and enhance the quality of life. For example, in June 2024, the National Health Service reported that 3,615,330 individuals were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, an 18% increase from 3,065,825 cases in 2022. Therefore, the growing number of diabetic patients is driving the expansion of the diabetes care drugs market.

Leading companies in the diabetes care drugs market are focusing on developing advanced treatments, such as fixed-ratio combination therapies, to improve glycemic control, simplify treatment regimens, and enhance patient adherence. Fixed-ratio combination therapies combine two complementary antidiabetic agents in a single injection, providing a more effective and convenient approach to managing diabetes. For instance, in April 2024, Sanofi SA, a France-based pharmaceutical company, launched Soliqua, a once-daily fixed-ratio combination of insulin glargine and lixisenatide for adults with type 2 diabetes and obesity. Soliqua combines long-acting insulin glargine for steady fasting glucose control with lixisenatide, a GLP-1 receptor agonist. This combination enhances glucose-dependent insulin secretion, suppresses glucagon production, and slows gastric emptying to reduce post-meal blood sugar levels, offering comprehensive daily glycemic management. The launch of Soliqua aims to simplify diabetes management, improve glycemic control, and increase patient adherence by reducing the need for multiple daily injections and minimizing potential side effects such as hypoglycemia and weight gain.

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired anti-diabetes trademarks from Boehringer Ingelheim International GmbH for an undisclosed amount. With this acquisition, Lupin now holds full trademark rights to GIBTULIO, GIBTULIO MET, and AJADUO, allowing the company to independently market these oral antidiabetic products across India and further expand its diabetes care portfolio. Boehringer Ingelheim International GmbH is a Germany-based pharmaceutical company, specializes in the manufacture of diabetes care drugs.

Major players in the diabetes care drugs market are Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GSK plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceuticals Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Insulet Corporation, Torrent Pharmaceuticals Ltd., Hanmi Pharmaceutical Limited, Hualan Biological, Wockhardt, Mitsubishi Tanabe Pharma, Gan & Lee Pharmaceuticals, DiogenX, Oramed Pharmaceuticals, and Apotex.

North America was the largest region in the diabetes care drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetes care drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diabetes care drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetes care drugs market consists of sales of oral antidiabetic drugs, non-insulin injectable drugs, and combination drugs. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The diabetes care drugs market research report is one of a series of new reports that provides diabetes care drugs market statistics, including the diabetes care drugs industry's global market size, regional shares, competitors with the diabetes care drugs market share, detailed diabetes care drugs market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care drugs market. This diabetes care drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Diabetes care drugs are medications used to manage blood glucose levels in individuals with diabetes mellitus, including type 1, type 2, and gestational diabetes. These drugs work by improving insulin production, enhancing insulin sensitivity, or reducing glucose absorption, with the primary goal of preventing complications by maintaining healthy blood sugar levels.

The primary drug classes in diabetes care include insulin, biguanides, sulfonylureas, dipeptidyl peptidase (DPP)-4 inhibitors, sodium-glucose co-transporter (SGLT)-2 inhibitors, glucagon-like peptide (GLP)-1 receptor agonists, thiazolidinediones, and alpha-glucosidase inhibitors. Insulin, a pharmaceutical version of the natural hormone, is administered through injection or inhalation to compensate for the body's insufficient production or utilization of insulin. These drugs are available in various formulations such as tablets, injections, solutions, gels, and extended-release formulations. They can be administered orally, by injection, or via inhalation, and are primarily used to manage Type 1 and Type 2 diabetes. These drugs are distributed through various channels, including hospital pharmacies and specialty pharmacies.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.